Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Go back to Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)| Merck & Co. (NYSE: MRK) | Delayed: 148.78 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.78 | 52 Week High | $65.46 | |||
| Open | $148.78 | 52 Week Low | $47.97 | |||
| Day High | $148.78 | P/E | 101.21 | |||
| Day Low | $148.78 | EPS | $1.47 | |||
| Volume | 16,122 | |||||
